Last reviewed · How we verify
NCT05775757: RASCO
SMC Radiation Oncology Breast Cancer Cohort Study
trial testing Hypofractionated radiation therapy in Radiotherapy Side Effect in 500 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Hypofractionated radiation therapy — full drug profile →
Conditions studied
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
Sponsor
Samsung Medical Center
Who can join
Adults 18 to 85, female only, with Radiotherapy Side Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about toxicities and cosmetic outcomes in breast cancer patients treated with hypofractionated radiotherapy. The main question it aims to answer are: * Changes in breast skin * Factors related to breast skin changes * Patient-reported outcomes * Cosmetic outcomes Participants will be assessed by multi-dimensional methods before and after radiotherapy: * Photographs * Fibrometer * Questionnaires (BREAST-Q) * CTCAE version 4.03 evaluated by treating physicians
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05775757
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypofractionated radiation therapy
Trials testing the same drug.
- NCT06325774 — Radical Hypofractionated Radiotherapy for Localized Prostate Cancer · NA · recruiting
- NCT06325995 — Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer · NA · recruiting
- NCT04318717 — Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma · Phase 2 · recruiting
- NCT03212235 — Hypofractionated Radiation Therapy for Glioblastoma · Phase 2 · unknown
- NCT02206230 — Trial of Hypofractionated Radiation Therapy for Glioblastoma · Phase 2 · completed
Other recruiting trials for Radiotherapy Side Effect
Currently open trials in the same condition.
- NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
- NCT06311955 — Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor · Phase 2 · recruiting
- NCT07008716 — Omitting CTV for Primary Tumor in LS-SCLC · Phase 3 · recruiting
- NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05775757 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05775757.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing